The role of prostate‐specific antigen changes in predicting overall survival after progressive‐site directed therapy for oligoprogressive castration‐resistant prostate cancer-Reference-Cited by-同舟云学术

The role of prostate‐specific antigen changes in predicting overall survival after progressive‐site directed therapy for oligoprogressive castration‐resistant prostate cancer

Published:2023-03-31 Issue:7 Volume:30 Page:616-617
ISSN:0919-8172
Container-title:International Journal of Urology
language:en
Short-container-title:Int J of Urology

Author:

Yoshida Soichiro¹,Takahara Taro²³,Tanaka Hajime¹^ORCID,Yokoyama Minato¹^ORCID,Yoshimura Ryoichi⁴,Fujii Yasuhisa¹^ORCID

Affiliation:

1. Department of Urology Tokyo Medical and Dental University Tokyo Japan

2. Department of Biomedical Engineering Tokai University School of Engineering Kanagawa Japan

3. Department of Radiology, Advanced Imaging Center Yaesu Clinic Tokyo Japan

4. Department of Radiation Therapeutics and Oncology Tokyo Medical and Dental University Tokyo Japan

Publisher

Wiley

Subject

Urology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1111/iju.15185

Reference6 articles.

1. Stereotactic Radiation for the Comprehensive Treatment of Oligometastases (SABR-COMET): Extended Long-Term Outcomes

2. Progressive Site-Directed Therapy for Castration-Resistant Prostate Cancer: Localization of the Progressive Site as a Prognostic Factor

3. Carbon 11-choline positron emission tomography/computed tomography and palliative local therapy for castration-resistant prostate cancer

4. Metastasis-directed Therapy Prolongs Efficacy of Systemic Therapy and Improves Clinical Outcomes in Oligoprogressive Castration-resistant Prostate Cancer

5. Stereotactic body radiotherapy for oligoprogressive lesions in metastatic castration‐resistant prostate cancer patients during abiraterone/enzalutamide treatment